Teijin and Axcelead sign deal for drug discovery research JV

并购引进/卖出
Teijin and Axcelead sign deal for drug discovery research JV
Preview
来源: Pharmaceutical Technology
The new company will support drug discovery research. Credit: Diane Serik / Unsplash.
Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company.
The new company will mainly use Teijin Group’s core healthcare company, Teijin Pharma’s drug discovery research capabilities, facilities, personnel, technologies, and equipment.
Its name, ownership ratio and other details are yet to be decided.
The two companies aim to conclude a final agreement within the fiscal year ending in March next year and then set up a new company shortly.
In addition to supporting drug discovery research, the new company will investigate and acquire candidate compounds for new drugs.
This new company is expected to increase drug discovery support services globally using Teijin and Axcelead’s combined strengths in drug-discovery knowledge, technology, and assets.
Teijin and Teijin Pharma are looking to innovate and boost drug discovery research through their alliance for the early launch of drugs for high medical requirements.
This basic agreement is also claimed to accord with the concept of co-creating drug discovery platforms of Axcelead.
Axcelead owns a group of companies that develop a healthcare platform for drug discovery.
Axcelead DDP is claimed to be the first integrated drug discovery solution provider in Japan.
It operates as the core company of the Axcelead group that took over Takeda Pharmaceutical Company’s drug discovery platform business in 2017.
Axcelead DDP is claimed to offer ‘one-stop’ nonclinical drug discovery research services ranging from drug-target discovery to optimisation of drug candidate compounds and approaches for linking to clinical development.
适应症
-
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。